METHODS:
We conducted an IRB approved retrospective chart review of all subjects who completed participation in an OIT clinical trial at our institution. RESULTS: Thirty-nine participants were included. Most participants were male (69.2%) and Caucasian (66.7 %). The average age was 9.9 years (range 4-17). Twenty-five (64.1%) consumed peanut products, 7 (17.9%) consumed peanut plus at least one other allergen, and 7 (17.9%) consumed wheat products. Following clinical trial completion, those subjects who achieved desensitization and expressed interest in maintaining protection were transitioned to consumption of commercially available food allergen. Currently, 23 (59.0 %) continue to ingest their culprit allergen from once daily to once every 2 weeks while 16 (41.0 %) have discontinued consumption due to adverse events (AEs) or personal preference. Three (7.7%) subjects stopped ingesting their food allergen as soon as the trials they were in was completed. 14 participants attended our post-trial clinic for continued up-dosing. Although reactions have occurred in this cohort, gastrointestinal symptoms/eosinophilic esophagitis have not developed. CONCLUSIONS: OIT is a successful desensitization method for food allergy, however not all post-trial subjects continue to ingest their allergen once desensitized. Those who transitioned to commercially available products containing their food allergen have been successful, and continued up-dosing has enabled participants to ingest greater amounts of their allergen(s) with few AEs. Black children, .0] of multiple/other race children have current FA. The proportion of foodallergic children reporting lifetime ED visits for FA treatment ranged from 37.4% of White children to 47.3% and 49.2% of Black and Hispanic children, respectively. Similar differences emerged when examining rates of FA-related ED visits in the last year. However, rates of physiciandiagnosed FA and current epinephrine auto-injector prescriptions did not differ significantly by race among individuals meeting stringent criteria for IgE-mediated FA after adjustment for demographics, FA characteristics and atopic comorbidities. In similarly adjusted models, odds of experiencing severe reaction symptoms did not differ by race, although foodallergic Black and Asian children had significantly elevated odds of multiple FAs compared to Whites (OR 1.9-2.0; p<.05). CONCLUSIONS: These national data indicate that FA prevalence and ED visit rates appear elevated among Black and Hispanic US children compared to their White and Asian peers.
